| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
| ln Vitro |
CYP4Z1-IN-1 (compound 7c) exhibits anti-proliferative action against breast cancer stem cells (CSCs) at an IC50 of 483 ± 2.5 nM[1]. In breast cancer cells, CYP4Z1-IN-1 (0.8-51.2 μM, 24 h) refluxes the expression of stem cell markers (P-gp, Oct3/4, Nanog, ALDH1A1, and Sox2) [1]. Breast cancer cells can migrate sparsely when exposed to CYP4Z1-IN-1 (0.8–51.2 μM, 24-48 hours).
|
|---|---|
| ln Vivo |
CYP4Z1-IN-1 (compound 7c) (2000 mg/kg, recently, for 7 days) has no obvious toxicity and weight loss in mice [1]. CYP4Z1-IN-1 (12.8 μM, 72 h treatment of MCF-7 and MDA-MB-231 cells, then subcutaneous tumor cells inguinal breast) can induce tumescent cell initiation [1].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: MCF-7 and MDA-MB-231 Cell Tested Concentrations: 0.8 μM, 3.2 μM, 12.8 μM, 51.2 μM Incubation Duration: 24 h Experimental Results: Significant inhibition of protein and solubility [1]. The expression of stemness markers (P-gp, Oct3/4, Nanog, ALDH1A1, and Sox2) in MCF-7 cells was concentration-dependent. |
| Animal Protocol |
Animal/Disease Models: Mice [1]
Doses: 2000 mg/kg Route of Administration: Orally for 7 days Experimental Results: Compound 7c is shown to be quite safe; no obvious toxicity and weight loss were observed. Animal/Disease Models: BALB/c-nude mice (3-4 weeks old, female) [1] Doses: 12.8 μM Route of Administration: MCF-7 and MDA-MB-231 cells were pretreated with 7c (12.8 μM) for 72 hrs (hrs (hours)) and then Implanted subcutaneously (sc) (sc) into the mouse inguinal mammary gland Experimental Results: Blocks the tumor-initiating ability of breast cancer cells. |
| References |
[1]. Yuan Y, et al. Identification of a Novel Potent CYP4Z1 Inhibitor Attenuating the Stemness of Breast Cancer Cells through Lead Optimization. J Med Chem. 2022 Dec 8;65(23):15749-15769.
|
| Molecular Formula |
C13H18N2O3
|
|---|---|
| Molecular Weight |
250.3
|
| Exact Mass |
250.13
|
| Elemental Analysis |
C, 62.38; H, 7.25; N, 11.19; O, 19.18
|
| CAS # |
2760611-38-7
|
| SMILES |
O=C(CCCC1=CC=C(C=C1)N/C=N/O)OCC
|
| InChi Key |
HJEKWTVRPSQJRV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H18N2O3/c1-2-18-13(16)5-3-4-11-6-8-12(9-7-11)14-10-15-17/h6-10,17H,2-5H2,1H3,(H,14,15)
|
| Chemical Name |
ethyl (E)-4-(4-(N'-hydroxyformimidamido)phenyl)butanoate
|
| Synonyms |
compound 7c; CYP4Z1-IN-1; CYP4Z1-IN 1; CYP4Z1 IN-1; CYP4Z1 Inhibitor 7c; CYP4Z1-IN-7c; GLXC-26590;
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9952 mL | 19.9760 mL | 39.9521 mL | |
| 5 mM | 0.7990 mL | 3.9952 mL | 7.9904 mL | |
| 10 mM | 0.3995 mL | 1.9976 mL | 3.9952 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
